FDA Pushes Leqembi Subcutaneous Start‑Dose Review to Aug. 24, 2026

Why It Matters

The extension of the FDA review period for Leqembi’s subcutaneous starter dose highlights the regulatory challenges facing amyloid‑targeting therapies, even after priority review status. A successful approval would give patients a less invasive, weekly injection option, potentially increasing adherence and expanding market penetration in the United States, the world’s largest Alzheimer’s drug market. Beyond patient convenience, the decision will signal how the FDA balances the need for rapid access to breakthrough therapies against the imperative to thoroughly evaluate safety signals such as ARIA. The outcome could set a precedent for future submissions of alternative dosing regimens for biologics in neurodegenerative diseases.

Key Takeaways

• FDA extends PDUFA date for Leqembi Iqlik start‑dose to Aug. 24, 2026, adding three months to the review.
• The agency requested additional data, classifying it as a major amendment to the sBLA.
• Leqembi is already approved for subcutaneous maintenance dosing and is sold in over 50 countries.
• A successful start‑dose approval could boost U.S. sales, which were part of a $1.2 billion global revenue in 2025.
• The delay occurs amid heightened scrutiny of amyloid‑targeting antibodies and their ARIA safety profile.

Pulse Analysis

Eisai and Biogen’s Leqembi has become a bellwether for the next wave of Alzheimer’s therapeutics. The original subcutaneous maintenance formulation already differentiated the drug from IV‑only competitors, and the planned weekly starter dose promised to further erode the logistical barriers that have limited uptake of anti‑amyloid antibodies. By extending the review, the FDA is effectively demanding a more granular safety and efficacy narrative, likely driven by lingering concerns over ARIA events that have plagued the class. This cautious stance may temper investor enthusiasm in the short term, but it also forces the sponsors to shore up their data packages, potentially resulting in a more robust label that could allay prescriber hesitancy.

From a market dynamics perspective, the delay could temporarily benefit rivals such as donanemab, which is pursuing its own subcutaneous formulation, and aducanumab, which remains under scrutiny. However, Leqembi’s extensive regulatory footprint—approval in 53 countries and a strong pipeline of ongoing submissions—means that a later U.S. decision is unlikely to derail its overall commercial trajectory. Instead, the extended timeline may allow Eisai and Biogen to fine‑tune their launch strategy, align payer negotiations, and address any residual safety concerns, ultimately positioning Leqembi for a more sustainable market share once the decision is rendered.

Looking ahead, the August decision will be a litmus test for how the FDA balances expedited pathways with rigorous data demands for biologics targeting complex neurodegenerative diseases. A favorable outcome could reinforce the agency’s willingness to grant flexible dosing options, encouraging other developers to pursue similar subcutaneous or oral formulations. Conversely, a negative or further delayed decision could signal a tightening of the regulatory environment, prompting sponsors to invest more heavily in early‑stage safety data before seeking label expansions.